Skip to main content

Advertisement

Fig. 2 | BMC Cancer

Fig. 2

From: Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients

Fig. 2

Sanger sequencing validation of some KRAS mutations. All 11 KRAS mutations identified by NGS were also validated by using Sanger sequencing. The figure shows a comparison between NGS and Sanger sequencing results for four KRAS mutations. On the left are displayed Sanger chromatograms, while results of NGS, showing read alignment to the reference genome, are on the right of the panel

Back to article page